Effect of perioperative application of cilvelestat sodium on lung function in patients undergoing thoracoscopic heart surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400084593

Enrollment

Unknown

Registered

2024-05-21

Start date

2024-06-01

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Valvular heart disease

Interventions

Experimental group:Add cilvelestat sodium at the beginning of cardiopulmonary bypass

Control group:Equal volume normal saline is added at the beginning of cardiopulmonary bypass

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients aged 18-65 years old, gender is not limited; (2) ASA grade I-III; (3) Cardiac function grade I-II; (4) Patients give informed consent and sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Chronic respiratory diseases (2) Severe left heart dysfunction (3) In the rheumatic active infection period (4) Immune diseases (5) Blood diseases (6) Liver and kidney dysfunction (7) Previous history of sivelestat allergy (8) History of cardiac surgery (9) Pregnant and lactating women (10) Patients who refused to participate (11) Others not suitable for clinical trials

Design outcomes

Primary

Measure	Time frame
oxygenation index;alveola-arterial partial oxygen pressure difference (A-aDo2);respiratory index (RI); incidence of postoperative pneumonia;	—

Secondary

Measure	Time frame
Pulse oxygen saturation;	—

Countries

China

Contacts

Public ContactZhou Lifang

The First Affiliated Hospital of Guangxi Medical University

395270146@qq.com+86 183 7881 1663

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026